Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $54.5 million.

  • Corcept Therapeutics' Cash from Operations fell 2566.68% to $54.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $163.4 million, marking a year-over-year increase of 1335.93%. This contributed to the annual value of $198.1 million for FY2024, which is 5591.04% up from last year.
  • As of Q3 2025, Corcept Therapeutics' Cash from Operations stood at $54.5 million, which was down 2566.68% from $43.9 million recorded in Q2 2025.
  • Over the past 5 years, Corcept Therapeutics' Cash from Operations peaked at $73.3 million during Q3 2024, and registered a low of $5.1 million during Q1 2025.
  • Its 5-year average for Cash from Operations is $37.7 million, with a median of $41.2 million in 2024.
  • As far as peak fluctuations go, Corcept Therapeutics' Cash from Operations plummeted by 8236.79% in 2023, and later soared by 91630.71% in 2024.
  • Over the past 5 years, Corcept Therapeutics' Cash from Operations (Quarter) stood at $49.4 million in 2021, then crashed by 32.45% to $33.4 million in 2022, then tumbled by 82.37% to $5.9 million in 2023, then skyrocketed by 916.31% to $59.8 million in 2024, then fell by 8.94% to $54.5 million in 2025.
  • Its Cash from Operations stands at $54.5 million for Q3 2025, versus $43.9 million for Q2 2025 and $5.1 million for Q1 2025.